Sign in
Taking peoplePhase 3

Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children

Key facts

Who runs it
Materia Medica Holding
Where
Russia30 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
264 people, planned
Started
3 Oct 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Rengalin
  • Placebo
Record updated
13 February 2026

Who can take part

Age
6 months to 3 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Outpatients of both genders aged over 6 months and under 3 years
  • Clinically confirmed diagnosis of acute viral upper respiratory tract infections (acute pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, tracheitis, acute viral respiratory infection of multiple and unspecified localization) during the epidemic growth of influenza and ARVI
  • Dry (non-productive) cough lasting at least 24 hours but not more than 72 hours
  • Total (day and night) cough severity score of 6 or more
  • Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by one of the patient's parents/adoptive parents

Who cannot take part

  • Taking medications listed in the section "Prohibited Concomitant Therapy" within 4 weeks prior to inclusion in the study
  • Patients whose parents/adoptive parents, from the investigator's point of view, will not comply with observation requirements during the study or with the administration of study drugs
  • Participation in other clinical trials within 3 months prior to inclusion in this trial
  • Presence of the following diseases at the time of inclusion in the clinical trial:; 1.1 Inflammatory processes in the lower respiratory tract. 1.2 Grade III adenoid hypertrophy. 1.3 Chronic adenoiditis. 1.4 Postnasal drip syndrome. 1.5 Gastroesophageal reflux. 1.6 Bronchial asthma. 1.7 Cystic fibrosis. 1.8 Primary ciliary dyskinesia 1.9 Bronchopulmonary dysplasia 1.10 Malformations of the respiratory and ENT organs 1.11 Other chronic lung diseases. 1.12 Primary/secondary immunodeficiency. 1.13 Oncological disease of any localization
  • Suspected bacterial infection of any localization, including pneumonia, sinusitis, otitis media
  • Allergic rhinitis
  • Bronchial obstruction syndrome
  • Congenital heart defects with hypervolemia in pulmonary circulation
  • Acute respiratory failure
  • Inflammatory, degenerative, demyelinating diseases of the central nervous system, polyneuropathies, epilepsy
  • Exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in a clinical trial
  • Presence of allergy/hypersensitivity to any components of the medicines used in the treatment
  • Acute obstructive laryngitis [croup] and epiglottitis
  • A patient's parent/adoptive parent is related to on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted
  • The patient's parent/adoptive parent is employed by OOO "NPF "MATERIA MEDICA HOLDING", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member

This trial is currently available in Russia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the efficacy and safety of liquid dosage form of Rengalin in the treatment of cough in acute viral upper respiratory tract infections infections in children in during the epidemic growth of influenza and ARVI. The main questions it aims to answer are:

Read full original descriptionShow less

Investigators will compare the liquid dosage form of Rengalin to a placebo (a look-alike substance that contains no drug) to see if Rengalin in the liquid dosage form works for cough in acute viral upper respiratory tract infections in children.

Participants will:

Take the liquid dosage form of Rengalin or placebo per os 5 ml per administration 3 times a day for 7 days.

The 2 groups in the trial

  • RengalinTreatment being tested

    Orally. 5 ml per dose 3 times a day for 7 days. The drug is taken without meals.

  • PlaceboPlacebo, for comparison

    Placebo using the dosing regimen Rengalin for 7 days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVI
Record updated
13 February 2026